PharmaSci
The computed 12-month bankruptcy probability of PharmaSci is 0.2% (very low). The company has been active since 2015 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.
| Active | 10 yrs |
| Locations | 1 |
| Publications | 1 |
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
| Fiscal year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2024 | verkort | 29-08-2025 | 2025-00463016 |
| 30-09-2023 | verkort | 04-04-2024 | 2024-00057133 |
| 30-09-2022 | verkort | 06-04-2023 | 2023-00055885 |
| 30-09-2021 | verkort | 14-02-2022 | 2022-05600219 |
| 30-09-2020 | verkort | 27-04-2021 | 2021-11600287 |
| 30-09-2019 | verkort | 03-02-2020 | 2020-04300030 |
| 30-09-2018 | verkort | 22-02-2019 | 2019-05600403 |
| 30-09-2017 | verkort | 29-03-2018 | 2018-08400126 |
| 30-09-2016 | verkort | 17-03-2017 | 2017-06600348 |
| NACE primary | Head offices & management consulting(70200) |
| Legal form | Private limited company(610) |
| Incorporation | 11-09-2015 |
| Status | Active |
| Postal code | 3110 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 24094D0492/00S002 | Flanders | 650 m² | 1 · 127 m² | 7.8 m · 2 fl. |
| 24094B0980/00K000 | Flanders | 490 m² | 1 · 339 m² | 10.6 m · 2 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
22-02-2024 Capital decrease of €1,855 to €4,345
- €6.200 → €4.345
Technical details
{
"events": [
{
"kind": "eenhoofdigheid_declaration",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "statutory_reserve_release",
"after_eur": 4345.0,
"delta_eur": -1855.0,
"before_eur": 6200.0,
"decrease_purpose": null,
"contribution_type": "reserves_incorporation",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": 12350.0,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_distributable"
},
{
"kind": "statutory_reserve_release",
"after_eur": null,
"delta_eur": null,
"before_eur": 12350.0,
"decrease_purpose": null,
"contribution_type": "reserves_incorporation",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
},
{
"kind": "statutory_reserve_release",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "suppress"
}
],
"notary": {
"name": "Herbert HOUBEN",
"firm_city": null,
"firm_name": null,
"office_city": "Genk",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2024-02-22",
"filing_date": "2024-02-20",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2023-12-29",
"unanimous": true,
"under_authorized_capital": true,
"underlying_resolution_date": "2023-12-29"
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0636.973.759",
"name_full": "PharmaSci",
"legal_form": "BV",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"expedition",
"geco\u00F6rdineerde statuten"
],
"shareholders_after": [],
"share_classes_after": [
{
"n_shares": 2500,
"class_name": "Gewone Aandelen",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
}
]
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | PharmaSci |